Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Miranda J. Toledano
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 21
- Beta
- 1.39
- Country
- IL
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -4.25
Financials
Revenue
$0.00-100.0%Net Income
$-7.31MEBITDA
$-4.56MFree Cash Flow
$-3.47MEPS (diluted)
$-0.14Shares Outstanding (diluted)
50.45M+324.1%Operating Expenses
$4.56MCash & Debt
$11.31MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $42.0K | $-11.44M | $-0.25 |
| 2024 | $181.0K | $-9.54M | $-0.25 |
| 2023 | $0.00 | $-8.89M | $-0.31 |
| 2022 | $134.0K | $-13.07M | $-0.45 |
| 2021 | $571.0K | $-12.19M | $-0.47 |
| 2020 | $365.0K | $-11.22M | $-0.54 |
| 2019 | $236.0K | $-10.79M | $-0.90 |
| 2018 | $500.0K | $-10.30M | $-0.91 |
| 2017 | $0.00 | $-11.20M | $-1.31 |
| 2016 | $0.00 | $-1.20M | $-0.14 |
| 2015 | $0.00 | $-4.28M | $-0.36 |
Valuation
ENTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150+1400.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·40d ago·Neutral
Correction: Entera to Participate in Upcoming Fall Investor Conferences TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief Executive Officer, Miranda Toledano, will be participating in the following upcoming fall investor conferences:
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
Entera to Participate in Upcoming Fall Investor Conferences TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief Executive Officer, Miranda Toledano, will be participating in the following upcoming fall investor conferences: 2026 Cantor Global Healthcare Conference Fireside Chat: September 10, 2026 at 1:00 p.m.
View source ↗ - Newsmarketbeat.com·53d ago·Negative
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement Entera Bio NASDAQ: ENTX plans to begin a Phase 3 study of its oral osteoporosis candidate EB613 after reaching agreement with the U.S. Food and Drug Administration on a 12-month, placebo-controlled registrational trial, Chief Executive Officer Miranda Toledano said during a discussion hosted by Canaccord Genuity.
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-0.07 per share
Typical surprise +22.2% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 7$-0.14 vs $-0.08miss
- Fri, May 8$-0.07 vs $-0.08beat
- Fri, Mar 27$-0.07 vs $-0.09beat
- Fri, Nov 14$-0.07 vs $-0.09beat
- Fri, Aug 8$-0.06 vs $-0.11beat
- Fri, May 9$-0.06 vs $-0.07beat
Estimates and results for ENTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ENTX officers and directors.
- Bought
- $230k
- Sold
- —
13 trades
0 trades
- Germano Geno Jbought
- Ellis Seanbought
- Taitel Hayabought
- Germano Geno Jbought
- Ellis Seanbought
- Toledano Miranda Jaynebought
- Taitel Hayabought
- Taitel Hayabought
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ENTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.